CHMP recommends Rixubis for treatment of Haemophilia B- Baxter
On 23 October 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rixubis, 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, powder and solvent for solution for injection from Baxter and intended for treatment and prophylaxis of bleeding in patients with Haemophilia B (congenital factor IX deficiency).
The benefits with Rixubis are its ability to achieve haemostatic efficacy for the prevention and treatment of bleeds in patients with Haemophilia B as well as efficacy during surgery. The most common side effects are dysgeusia, pain in extremity, anti Furin antibodies and postoperative anaemia.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins